A phase II clinical study showed that osimertinib plus bevacizumab is beneficial in the treatment of lung cancer brain metastases [14], and our previous study indicated that osimertinib plus bevacizumab was safe and effective for the treatment of LM in EGFR-mutant lung cancer [NCT04148898] [15]. Here, EGFR is linked to lymphangioma.